Cour Pharmaceuticals closes $50M Series B led by Lumira Ventures and Roche Venture Fund
What's the deal? Cour Pharmaceuticals is closing a $50 million Series B round led by Lumira VenturesDealroom has a profile for this one. Try Dealroom → and RocheDealroom has a profile for this one. Try Dealroom → Venture Fund , with participation from SanofiDealroom has a profile for this one. Try Dealroom →.
The round brings together two of the world's largest pharmaceutical companies as backers of the biotech startup, signalling strong strategic interest in its platform.
Why now? Big pharma's venture arms have been increasingly active in backing early-stage biotech companies that could feed their pipelines. Roche and Sanofi both participating suggests Cour's technology has attracted competitive interest from multiple pharma giants.
The signal: Cour Pharmaceuticals is developing nanoparticle technology designed to reset the immune system of multiple sclerosis patients — a therapeutic area where both Roche and Sanofi already have significant commercial stakes. Having two competing pharma giants co-invest in a late-stage biotech working on immune tolerance suggests the platform's potential extends well beyond a single indication, making it a pipeline asset worth sharing rather than fighting over.
Read more: ainvest.com
